JNJ vs LLY: six-factor score, head to head
How Johnson & Johnson and Eli Lilly & Co.compare on Tapeline’s published six-factor composite score. Descriptive only — a rules-based reading of each name, not a recommendation.
Today, JNJ scores 74 and LLY scores 66on Tapeline’s six-factor composite. JNJ carries the higher composite score today. Here’s how the six factors line up.
| Factor | JNJ | LLY |
|---|---|---|
| Trend | 95 | 91 |
| Relative Strength | 68 | 66 |
| Fundamentals | 80 | 83 |
| Smart Money | 38 | 11 |
| Macro | 75 | 75 |
| Momentum | 75 | 50 |
momentum factor in the top band of its score. smart-money factor above the score midpoint and trend factor below the score midpoint.
fundamentals factor above the score midpoint; relative-strength factor on the lower side vs healthcare peers.
The Tapeline Score is a descriptive, rules-based measure for information only — not investment advice or a recommendation to buy or sell. See the six-factor method and the public scorecard.
More comparisons
FAQ
- How do JNJ and LLY compare on Tapeline?
- Tapeline scores JNJ 74/100 and LLY 66/100 on its published six-factor composite (trend, relative strength, fundamentals, smart money, macro, momentum). The page breaks the two scores down factor by factor.
- Which has the higher Tapeline score, JNJ or LLY?
- JNJ has the higher composite score today (74 vs 66). The score is a descriptive measure, not a recommendation — see the per-factor breakdown above.
- Is this investment advice?
- No. Tapeline publishes a descriptive, rules-based six-factor score for information only. It is not a recommendation to buy or sell, and every top pick is back-checked publicly at /scorecard.